Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13469235 | 0.89 | EPAS1 (0.34) | EPAS1SLC22A12 | |
| SCHEMBL3958603 | 0.75 | EPAS1 (0.41) | EPAS1SLC22A12 | |
| SCHEMBL2125034 | 0.73 | IMPDH2 (0.54) | — | |
| SCHEMBL3606201 | 0.73 | EPAS1 (0.34) | EPAS1 | |
| SCHEMBL5728291 | 0.73 | EPAS1 (0.45) | EPAS1SLC22A12 | |
| SCHEMBL18585504 | 0.72 | XDH (0.41) | EPAS1SLC22A12 | |
| SCHEMBL22439123 | 0.72 | PDE4A (0.33) | EPAS1SLC22A12 | |
| SCHEMBL7572876 | 0.71 | EPAS1 (0.36) | EPAS1SLC22A12 | |
| SCHEMBL2259279 | 0.71 | AR (0.44) | EPAS1SLC22A12 | |
| SCHEMBL3627292 | 0.71 | EPAS1 (0.38) | EPAS1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946195-B2 | Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140206652-A1 | BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8716267-B2 | Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120264718-A1 | BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. | 2012-10-18 | — | — | US | disclosed |
| WO-2012142377-A1 | BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206652-A1 | BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | S1PR1, S1PR3, S1PR2 | EPAS1 1473/4885SLC22A12 3795/4885 |
| US-20120264718-A1 | BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | S1PR1, S1PR3, S1PR2 | EPAS1 1473/4885SLC22A12 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.